Latest market price
45.69
+0.80+1.78%
OverviewShort InterestFilings
ALKSQT57Alkermes plc·NASDAQ
45.69+1.78%
Filing
Up 1.8% — Filed an 8-K material-event report (2026-11-03) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
LNTH+0.49%$100.80AMRX-1.13%$20.21RDY+1.20%$14.30ELAN+1.95%$24.57INDV+2.57%$36.28RGC-2.23%$6.15BHC+1.50%$8.14VTRS+1.34%$18.92
Snapshot
Index—P/E118.13EPS (ttm)0.38Insider Own1.90%Shs Outstand167.76MPerf Week3.09%
Market Cap7.53BForward P/E82.42EPS next Y0.54Insider Trans-3.65%Shs Float155.19MPerf Month6.85%
Enterprise Value8.44BPEG—EPS next Q-0.08Short Float12.27%Perf Quarter-7.90%
Income67.00MP/S4.51EPS this Y-131.10%Short Ratio10.25Perf Half Y26.04%
Sales1.67BP/B4.16EPS next Y—ROA1.51%Short Interest19.05MPerf YTD63.30%
Book/sh10.78P/C11.46EPS next 5Y—ROE3.72%52W High55.67 -17.93%Perf Year48.83%
Cash/sh3.92P/FCF34.08EPS past 3/5Y—ROIC2.12%52W Low27.00 69.22%Perf 3Y91.17%
Dividend Est.—EV/EBITDA38.72Sales past 3/5Y9.90% 7.27%Gross Margin84.56%Volatility3.68% 3.40%Perf 5Y45.00%
Dividend TTM—EV/Sales5.06EPS Y/Y TTM-81.59%Oper. Margin7.03%ATR (14)1.54Perf 10Y-19.40%
Dividend Ex-Date—Quick Ratio1.85Sales Y/Y TTM10.76%Profit Margin3.96%RSI (14)61.73Recom2.55
Dividend Gr. 3/5Y—Current Ratio2.30EPS Q/Q34.62%SMA206.72%Beta0.23Target Price58.29
Payout0.00%Debt/Eq0.87Sales Q/Q26.85%SMA504.02%Rel Volume1.25Prev Close44.89
Employees2,050LT Debt/Eq0.85EarningsFeb 24SMA20012.50%Avg Volume1.86MPrice45.69
IPO DateJul 16, 1991Option/ShortYes / YesEPS/Sales Surpr.2649.81% 8.45%Net Debt/EBITDA4.17Volume2,328,578Change1.78%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-16-26ReiteratedTruist FinancialBuy$55
Sep-24-26ResumedGoldman SachsNeutral$35 → $50
Jul-28-26ReiteratedPiper SandlerOverweight$45 → $65
Jul-20-26ReiteratedStifel Nicolaus$36 → $63
Jul-02-26ReiteratedMizuhoOutperform$45 → $65
Jun-29-26DowngradeB of A SecuritiesNeutral → Underperform
Jun-18-26ReiteratedNeedhamBuy$50 → $54
Jun-09-26ReiteratedRBC CapitalOutperform$47 → $56
May-06-26ReiteratedNeedhamBuy$43 → $50
Feb-26-26ReiteratedH.C. WainwrightNeutral$46 → $43
Latest News· Times ET
Today
Today07:15PM
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcriptseekingalpha.com
04:28PM
Alkermes (ALKS) Q3 2026 Earnings Call TranscriptYahoo
01:17PM
What Alkermes (ALKS) Said on Its Q3 Earnings Callmarketbeat.com
10:31AM
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Sayzacks.com
09:16AM
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimateszacks.com
07:05AM
Alkermes plc Reports Third Quarter 2026 Financial Resultsbusinesswire.com
03:45AM
Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrastdefenseworld.net
Oct-30-26
Oct-30-2607:00AM
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)businesswire.com
Oct-29-26
Oct-29-2602:39PM
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Storyseekingalpha.com
Oct-27-26
Oct-27-2609:00AM
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineYahoo
Oct-26-26
Oct-26-2604:57AM
Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V.defenseworld.net
Oct-20-26
Oct-20-2604:00PM
Alkermes to Report Third Quarter Financial Results on November 3, 2026businesswire.com
11:06AM
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Declinezacks.com
03:53AM
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenuedefenseworld.net
Oct-16-26
Oct-16-2609:38AM
Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst callsYahoo
Company

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,6681,4761,5581,663—————
Cost of Goods Sold Incl. D&A258196245253—————
Gross Profit1,4101,2791,3121,410—————
Selling, General and Administrative Excl. Other845715645690—————
Research and Development391324245271—————
Other Operating Expense58-14235—————
Operating Income117254421414—————
Interest Expense59122323—————
Unusual Expense
—————————
Non-Operating Income (Expense)40504630—————
Net Income Before Taxes97291444422—————
Income Taxes325072-98—————
Consolidated Net Income67242367356—————
Net Income From Continuing Operations67242372519—————
Net Income67242367356—————
EPS (Recurring)0.401.472.222.14—————
EPS (Basic, Before Extraordinaries)0.401.472.222.14—————
EPS (Diluted)0.381.432.172.10—————
EBITDA218331495519—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio120.2419.5713.2513.21—————
Price To Sales Ratio4.573.133.052.77—————
Gross Margin84.5386.6584.2184.79—————
Operating Margin7.0117.2127.0224.89—————
Net Margin4.0216.4023.5621.41—————
Shares Outstanding167165165166—————
Market Capitalization7,6304,6174,7454,605—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$59.52$50.20$40.87$31.54$22.21● Close Price0.00M0.79M1.57M2.36M3.15MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gaffin David JosephEVP, CLO, Alkermes, Inc.Nov 03 '26Sale46.172,03593,956219,353Nov 03
Reed JoshuaSVP, Chief Financial OfficerOct 08 '26Option Exercise0.009,16409,164Oct 09
Gaffin David JosephEVP, CLO, Alkermes, Inc.Oct 02 '26Sale41.032,03483,455221,388Oct 02
Gaffin David JosephEVP, CLO, Alkermes, Inc.Sep 03 '26Sale48.012,03497,652223,422Sep 03
Hopkinson Craig C.EVP R&D, Chief Medical OfficerSep 01 '26Option Exercise24.595,000122,95074,389Sep 01
Hopkinson Craig C.EVP R&D, Chief Medical OfficerSep 01 '26Sale46.999,000422,87465,389Sep 01
Nichols Christian ToddSVP, Chief Commercial OfficerAug 17 '26Sale49.237,576372,936102,193Aug 17
snyderman nancy lynn MDDirectorAug 03 '26Option Exercise46.7244,4722,077,73259,867Aug 03
snyderman nancy lynn MDDirectorAug 03 '26Sale50.3544,4722,239,07615,395Aug 03
Hopkinson Craig C.EVP R&D, Chief Medical OfficerAug 03 '26Option Exercise24.485,000122,40478,389Aug 03
Hopkinson Craig C.EVP R&D, Chief Medical OfficerAug 03 '26Sale48.589,000437,22069,389Aug 03
Gaffin David JosephEVP, CLO, Alkermes, Inc.Aug 03 '26Sale48.582,03498,812225,456Aug 03
Gaffin David JosephEVP, CLO, Alkermes, Inc.Jul 06 '26Sale54.032,034109,897227,490Jul 06
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJul 01 '26Sale51.519,000463,62173,389Jul 01
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJul 01 '26Option Exercise19.345,00096,70082,389Jul 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.